JP2018501794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501794A5 JP2018501794A5 JP2017533969A JP2017533969A JP2018501794A5 JP 2018501794 A5 JP2018501794 A5 JP 2018501794A5 JP 2017533969 A JP2017533969 A JP 2017533969A JP 2017533969 A JP2017533969 A JP 2017533969A JP 2018501794 A5 JP2018501794 A5 JP 2018501794A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- car
- sequence encoding
- spacer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206023A JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1423172.4 | 2014-12-24 | ||
| GB201423172 | 2014-12-24 | ||
| PCT/GB2015/054137 WO2016102965A1 (en) | 2014-12-24 | 2015-12-23 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206023A Division JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501794A JP2018501794A (ja) | 2018-01-25 |
| JP2018501794A5 true JP2018501794A5 (enExample) | 2019-06-20 |
| JP6633081B2 JP6633081B2 (ja) | 2020-01-22 |
Family
ID=55066668
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533969A Active JP6633081B2 (ja) | 2014-12-24 | 2015-12-23 | 細胞 |
| JP2019206023A Active JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
| JP2020199333A Active JP7514746B2 (ja) | 2014-12-24 | 2020-12-01 | 細胞 |
| JP2021170769A Withdrawn JP2022002546A (ja) | 2014-12-24 | 2021-10-19 | 細胞 |
| JP2024032851A Pending JP2024055976A (ja) | 2014-12-24 | 2024-03-05 | 細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206023A Active JP6909844B2 (ja) | 2014-12-24 | 2019-11-14 | 細胞 |
| JP2020199333A Active JP7514746B2 (ja) | 2014-12-24 | 2020-12-01 | 細胞 |
| JP2021170769A Withdrawn JP2022002546A (ja) | 2014-12-24 | 2021-10-19 | 細胞 |
| JP2024032851A Pending JP2024055976A (ja) | 2014-12-24 | 2024-03-05 | 細胞 |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US11091532B2 (enExample) |
| EP (3) | EP4368704A3 (enExample) |
| JP (5) | JP6633081B2 (enExample) |
| KR (6) | KR102085349B1 (enExample) |
| CN (3) | CN114107212A (enExample) |
| AU (5) | AU2015370679C1 (enExample) |
| BR (1) | BR112017013690A2 (enExample) |
| CA (2) | CA2970440A1 (enExample) |
| CL (3) | CL2017001314A1 (enExample) |
| DK (2) | DK3560953T5 (enExample) |
| ES (2) | ES2744910T3 (enExample) |
| FI (1) | FI3560953T3 (enExample) |
| HR (1) | HRP20240357T1 (enExample) |
| HU (2) | HUE046262T2 (enExample) |
| IL (5) | IL301458A (enExample) |
| LT (1) | LT3560953T (enExample) |
| MX (1) | MX2017006233A (enExample) |
| PL (2) | PL3237442T3 (enExample) |
| PT (2) | PT3237442T (enExample) |
| RS (1) | RS65343B1 (enExample) |
| RU (2) | RU2022102250A (enExample) |
| SG (2) | SG11201704084VA (enExample) |
| SI (1) | SI3560953T1 (enExample) |
| SM (1) | SMT202400134T1 (enExample) |
| WO (1) | WO2016102965A1 (enExample) |
| ZA (1) | ZA201703381B (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201415347D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| IL301458A (en) | 2014-12-24 | 2023-05-01 | Autolus Ltd | A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD |
| US10765699B2 (en) * | 2015-02-06 | 2020-09-08 | National University Of Singapore | Methods for enhancing efficacy of therapeutic immune cells |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| GB201507115D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| TW202444897A (zh) | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| CA3035615A1 (en) * | 2016-09-02 | 2018-03-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| WO2018108106A1 (zh) * | 2016-12-13 | 2018-06-21 | 科济生物医药（上海）有限公司 | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 |
| CN110121505B (zh) * | 2016-12-28 | 2023-08-01 | 株式会社绿十字细胞治疗 | 嵌合抗原受体和表达其的自然杀伤细胞 |
| EP3568466A4 (en) | 2017-01-10 | 2020-07-15 | The General Hospital Corporation | TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| MX2019010812A (es) | 2017-03-17 | 2019-12-11 | Hutchinson Fred Cancer Res | Proteinas de fusion inmunomoduladoras y sus usos. |
| CA3059444A1 (en) * | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| EP3612568B8 (en) * | 2017-04-18 | 2021-12-08 | Autolus Limited | Cell |
| US11344578B2 (en) | 2017-04-19 | 2022-05-31 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CA3062433A1 (en) * | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| JP2020524512A (ja) | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| CN111247241A (zh) | 2017-08-10 | 2020-06-05 | 新加坡国立大学 | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 |
| CN109385402A (zh) * | 2017-08-11 | 2019-02-26 | 上海恒润达生生物科技有限公司 | 一种等比例混合两种靶点cart细胞的制备方法及应用 |
| CN107446937B (zh) * | 2017-09-05 | 2020-12-25 | 深圳华云生物技术有限公司 | 嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用 |
| CN111148533A (zh) | 2017-09-19 | 2020-05-12 | 麻省理工学院 | 用于嵌合抗原受体t细胞疗法的组合物及其用途 |
| WO2019079249A1 (en) * | 2017-10-16 | 2019-04-25 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
| CN108101994B (zh) * | 2018-01-04 | 2020-09-15 | 广东万海细胞生物科技有限公司 | 抗cd19抗体及其应用 |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| WO2019156795A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| CN110157738B (zh) * | 2018-02-13 | 2023-06-27 | 亘喜生物科技（上海）有限公司 | 靶向cd19和cd22的工程化免疫细胞及其应用 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| AU2019269118B2 (en) * | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| EP3784776A4 (en) | 2018-05-23 | 2022-01-26 | National University of Singapore | Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies |
| KR20210031898A (ko) * | 2018-07-13 | 2021-03-23 | 난징 레전드 바이오테크 씨오., 엘티디. | 전염병을 치료하기 위한 공동수용체 시스템 |
| FI3856775T3 (fi) | 2018-09-27 | 2024-12-04 | Autolus Ltd | Kimeerinen antigeenireseptori |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| GB201816522D0 (en) | 2018-10-10 | 2018-11-28 | Autolus Ltd | Methods and reagents for analysing nucleic acids from single cells |
| GB201820547D0 (en) | 2018-12-17 | 2019-01-30 | Oxford Univ Innovation | Modified antibodies |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| AU2020275049A1 (en) * | 2019-05-16 | 2022-01-06 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells comprsing a recognition molecule |
| JP2022535138A (ja) * | 2019-06-07 | 2022-08-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｃｄ２８および４－１ｂｂに個々に連結したデュアルｃａｒを発現するｔ細胞 |
| CN114258398A (zh) | 2019-06-13 | 2022-03-29 | 总医院公司 | 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法 |
| US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| WO2021009510A1 (en) | 2019-07-16 | 2021-01-21 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| JP7802651B2 (ja) | 2019-08-07 | 2026-01-20 | アクアラン セラピューティクス コーポレーション | 抗ｎａｍｐｔ抗体及びその用途 |
| CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
| CN110903401A (zh) * | 2019-11-20 | 2020-03-24 | 浙江大学 | 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用 |
| EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| KR20220104217A (ko) * | 2019-11-26 | 2022-07-26 | 노파르티스 아게 | Cd19 및 cd22 키메라 항원 수용체 및 이의 용도 |
| KR20220163940A (ko) | 2020-02-04 | 2022-12-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 항-디니트로페놀 키메라 항원 수용체 |
| CA3169804A1 (en) * | 2020-02-04 | 2021-08-12 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells |
| JP7545139B2 (ja) * | 2020-03-11 | 2024-09-04 | フンダシオ インスティテュート デ レセルカ コントラ ラ レウセミア ジュゼップ カレラス | Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分 |
| WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
| WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| CN116157510A (zh) | 2020-06-17 | 2023-05-23 | 詹森生物科技公司 | 用于制造多能干细胞的材料和方法 |
| WO2022012680A1 (en) | 2020-07-16 | 2022-01-20 | Nanjing Legend Biotech Co., Ltd. | Cd20 binding molecules and uses thereof |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| JP2023540222A (ja) * | 2020-08-25 | 2023-09-22 | サイトイミューン セラピューティクス， インコーポレイテッド | 二特異性抗体ｃａｒ細胞免疫療法 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| CN112481284B (zh) * | 2020-12-07 | 2023-07-25 | 深圳瑞吉生物科技有限公司 | 一种编码CAR基因的mRNA、组合mRNA、构建方法、CAR-T细胞和应用 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| KR102393776B1 (ko) | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| AU2022227021A1 (en) * | 2021-02-26 | 2023-09-21 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| WO2022269473A1 (en) | 2021-06-23 | 2022-12-29 | Janssen Biotech, Inc. | Materials and methods for hinge regions in functional exogenous receptors |
| WO2023016554A1 (zh) * | 2021-08-13 | 2023-02-16 | 上海医药集团股份有限公司 | 靶向cd22的抗原结合蛋白及其用途 |
| KR102829757B1 (ko) * | 2021-11-17 | 2025-07-09 | (주)이노베이션바이오 | 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체 |
| EP4522204A1 (en) | 2022-05-11 | 2025-03-19 | Autolus Limited | Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia |
| US20250188492A1 (en) | 2022-07-22 | 2025-06-12 | Janssen Biotech, Inc. | Enhanced Transfer of Genetic Instructions to Effector Immune Cells |
| US20240197780A1 (en) * | 2022-12-19 | 2024-06-20 | Development Center For Biotechnology | Chimeric antigen receptors, nucleic acids encoding the same, and uses thereof in treating cancers |
| JP2026510945A (ja) * | 2023-03-17 | 2026-04-10 | カーティザン セラピューティクス，インコーポレーテッド | キメラ抗原受容体の長期発現に適応した細胞内シグナル伝達および共刺激ドメイン |
| EP4719463A1 (en) | 2023-05-30 | 2026-04-08 | Autolus Limited | Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia |
| WO2024250037A1 (en) * | 2023-06-02 | 2024-12-05 | Northeastern University | Targeted immune cell therapy utilizing trail and tnf mediated apoptosis |
| AU2024365682A1 (en) | 2023-10-23 | 2026-04-30 | Autolus Limited | Products and methods for treating autoimmune diseases |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| WO2025215360A1 (en) | 2024-04-09 | 2025-10-16 | Autolus Limited | Method |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
| NL2037929B1 (en) | 2024-06-11 | 2026-01-12 | Prinses Maxima Centrum Voor Kinderoncologie B V | Brain Organoid |
| CN121896173A (zh) | 2024-10-21 | 2026-04-21 | 深圳市湾岛细胞科技有限公司 | 表达外源肌苷单磷酸脱氢酶的真核细胞 |
| WO2026096515A1 (en) | 2024-10-28 | 2026-05-07 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2299011A1 (fr) | 1975-01-29 | 1976-08-27 | Obert Jean Claude | Generateur d'aerosols de part |
| AU4418900A (en) | 1999-04-16 | 2000-11-02 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| AU2001297703B2 (en) * | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| AU2004242846A1 (en) * | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| SI1976886T1 (sl) | 2005-12-16 | 2015-03-31 | Amgen Research (Munich) Gmbh | Sredstva in postopki za zdravljenje tumorskih bolezni |
| EP2389443B1 (en) * | 2009-01-23 | 2018-11-14 | Roger Williams Hospital | Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| IN2014CN02906A (enExample) * | 2011-10-20 | 2015-07-03 | Us Health | |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| AU2013289971A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| RU2658485C2 (ru) | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
| AU2014214850C1 (en) * | 2013-02-06 | 2018-12-06 | Celgene Corporation | Modified T lymphocytes having improved specificity |
| EP3241897B1 (en) | 2013-03-07 | 2018-10-03 | Baylor College of Medicine | Targeting cd138 in cancer |
| JP6857028B2 (ja) | 2013-03-15 | 2021-04-14 | メモリアル スローン ケタリング キャンサー センター | 免疫治療のための組成物および方法 |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| RS63798B1 (sr) | 2013-05-13 | 2022-12-30 | Cellectis | Cd19 specifični himerni antigenski receptor i njegove primene |
| JP6585041B2 (ja) | 2013-07-18 | 2019-10-02 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 免疫細胞の能力を増強する方法 |
| MX377283B (es) | 2013-11-21 | 2025-03-07 | Ucl Business Ltd | Célula t o nk que coexpresa un receptor antigénico quimérico (car). |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| IL301458A (en) | 2014-12-24 | 2023-05-01 | Autolus Ltd | A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201507111D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| TW202444897A (zh) * | 2015-06-25 | 2024-11-16 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體(car)、組合物及其使用方法 |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| AU2019269118B2 (en) | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
-
2015
- 2015-12-23 IL IL301458A patent/IL301458A/en unknown
- 2015-12-23 AU AU2015370679A patent/AU2015370679C1/en active Active
- 2015-12-23 HR HRP20240357TT patent/HRP20240357T1/hr unknown
- 2015-12-23 RS RS20240357A patent/RS65343B1/sr unknown
- 2015-12-23 SM SM20240134T patent/SMT202400134T1/it unknown
- 2015-12-23 PL PL15817520T patent/PL3237442T3/pl unknown
- 2015-12-23 IL IL274903A patent/IL274903B/en unknown
- 2015-12-23 CN CN202111208410.1A patent/CN114107212A/zh active Pending
- 2015-12-23 CN CN201580065695.4A patent/CN107002045B/zh active Active
- 2015-12-23 KR KR1020177019393A patent/KR102085349B1/ko active Active
- 2015-12-23 HU HUE15817520A patent/HUE046262T2/hu unknown
- 2015-12-23 DK DK19172397.2T patent/DK3560953T5/da active
- 2015-12-23 FI FIEP19172397.2T patent/FI3560953T3/fi active
- 2015-12-23 EP EP23217769.1A patent/EP4368704A3/en active Pending
- 2015-12-23 HU HUE19172397A patent/HUE066020T2/hu unknown
- 2015-12-23 CN CN202511437174.9A patent/CN121427832A/zh active Pending
- 2015-12-23 KR KR1020197038792A patent/KR20200003939A/ko not_active Ceased
- 2015-12-23 IL IL292508A patent/IL292508B2/en unknown
- 2015-12-23 KR KR1020237036909A patent/KR20230152824A/ko active Pending
- 2015-12-23 PT PT15817520T patent/PT3237442T/pt unknown
- 2015-12-23 CA CA2970440A patent/CA2970440A1/en active Pending
- 2015-12-23 ES ES15817520T patent/ES2744910T3/es active Active
- 2015-12-23 JP JP2017533969A patent/JP6633081B2/ja active Active
- 2015-12-23 BR BR112017013690-2A patent/BR112017013690A2/pt not_active Application Discontinuation
- 2015-12-23 SG SG11201704084VA patent/SG11201704084VA/en unknown
- 2015-12-23 CA CA3224507A patent/CA3224507A1/en active Pending
- 2015-12-23 LT LTEP19172397.2T patent/LT3560953T/lt unknown
- 2015-12-23 PL PL19172397.2T patent/PL3560953T3/pl unknown
- 2015-12-23 US US15/529,690 patent/US11091532B2/en active Active
- 2015-12-23 IL IL326644A patent/IL326644A/en unknown
- 2015-12-23 SG SG10202111107RA patent/SG10202111107RA/en unknown
- 2015-12-23 RU RU2022102250A patent/RU2022102250A/ru unknown
- 2015-12-23 WO PCT/GB2015/054137 patent/WO2016102965A1/en not_active Ceased
- 2015-12-23 EP EP15817520.8A patent/EP3237442B1/en not_active Revoked
- 2015-12-23 KR KR1020217024459A patent/KR102376244B1/ko active Active
- 2015-12-23 PT PT191723972T patent/PT3560953T/pt unknown
- 2015-12-23 KR KR1020217024458A patent/KR102376242B1/ko active Active
- 2015-12-23 MX MX2017006233A patent/MX2017006233A/es active IP Right Grant
- 2015-12-23 RU RU2017121892A patent/RU2768019C2/ru active
- 2015-12-23 KR KR1020227031979A patent/KR20220129684A/ko not_active Ceased
- 2015-12-23 EP EP19172397.2A patent/EP3560953B1/en active Active
- 2015-12-23 DK DK15817520.8T patent/DK3237442T3/da active
- 2015-12-23 SI SI201531999T patent/SI3560953T1/sl unknown
- 2015-12-23 ES ES19172397T patent/ES2976197T3/es active Active
-
2017
- 2017-05-10 IL IL252208A patent/IL252208B/en unknown
- 2017-05-16 ZA ZA2017/03381A patent/ZA201703381B/en unknown
- 2017-05-23 CL CL2017001314A patent/CL2017001314A1/es unknown
- 2017-06-23 US US15/632,119 patent/US10174099B2/en active Active
- 2017-06-23 US US15/631,948 patent/US10098926B2/en active Active
-
2018
- 2018-06-29 US US16/024,445 patent/US10981970B2/en active Active
- 2018-11-13 CL CL2018003217A patent/CL2018003217A1/es unknown
- 2018-11-13 CL CL2018003216A patent/CL2018003216A1/es unknown
- 2018-12-06 US US16/211,538 patent/US11034750B2/en active Active
-
2019
- 2019-11-14 JP JP2019206023A patent/JP6909844B2/ja active Active
-
2020
- 2020-02-07 US US16/785,467 patent/US20200181232A1/en not_active Abandoned
- 2020-08-06 AU AU2020213352A patent/AU2020213352B2/en active Active
- 2020-12-01 JP JP2020199333A patent/JP7514746B2/ja active Active
-
2021
- 2021-10-19 JP JP2021170769A patent/JP2022002546A/ja not_active Withdrawn
-
2022
- 2022-07-12 AU AU2022205170A patent/AU2022205170B2/en active Active
- 2022-07-12 AU AU2022205169A patent/AU2022205169B2/en active Active
-
2023
- 2023-01-24 US US18/158,754 patent/US12398194B2/en active Active
-
2024
- 2024-03-05 JP JP2024032851A patent/JP2024055976A/ja active Pending
- 2024-12-10 AU AU2024278248A patent/AU2024278248A1/en active Pending
-
2025
- 2025-07-25 US US19/281,399 patent/US20250353893A1/en active Pending